Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity

View ORCID ProfileJulien Favresse, Jean-Louis Bayart, Clara David, Constant Gillot, Grégoire Wieërs, Gatien Roussel, Guillaume Sondag, Marc Elsen, Christine Eucher, Jean-Michel Dogné, View ORCID ProfileJonathan Douxfils
doi: https://doi.org/10.1101/2021.11.18.21266478
Julien Favresse
1Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
2Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Julien Favresse
Jean-Louis Bayart
3Department of Laboratory Medicine, Clinique St-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clara David
4Qualiblood sa, Namur, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Constant Gillot
2Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grégoire Wieërs
5Department of Internal Medicine, Clinique Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gatien Roussel
3Department of Laboratory Medicine, Clinique St-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillaume Sondag
1Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Elsen
1Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Eucher
1Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Michel Dogné
2Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Douxfils
2Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium
4Qualiblood sa, Namur, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jonathan Douxfils
  • For correspondence: jonathan.douxfils@unamur.be
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The diagnostic of SARS-CoV-2 infection relies on reverse transcriptase polymerase chain reactions (RT-PCR) performed on nasopharyngeal (NP) swabs. Nevertheless, false negative results can be obtained with inadequate sampling procedures making the use of other matrices of interest. This study aims at evaluating the kinetic of serum N antigen in severe and non-severe patients and compare the clinical performance of serum antigenic assays with NP RT-PCR. Ninety patients were included and monitored for several days. Disease severity was determined according to the WHO clinical progression scale. The serum N antigen was measured with a chemiluminescent assay (CLIA) and the Single Molecular Array (Simoa). Thresholds for severity were determined. In severe patients, the peak antigen response was observed 7 days after the onset of symptoms followed by a decline. No peak response was observed in non-severe patients. Severity threshold for the Simoa and the CLIA provided positive likelihood ratio of 30.0 and 10.9 for the timeframe between day 2 and day 14, respectively. Compared to NP RT-PCR, antigenic assays were able to discriminate the severity of the disease (p = 0.0174, 0.0310 and p = 0.1551 with the Simoa, the CLIA and the NP RT-PCR, respectively). Sensitive N antigen detection in serum thus provides a valuable new marker for COVID-19 diagnosis and evaluation of disease severity. When assessed during the first 2 weeks since the onset of symptoms, it may help in identifying patients at risk of developing severe COVID-19 to optimize better intensive care utilization.

Competing Interest Statement

YHLO provided the kits for the iFlash antigen assays and JDO received honorarium from YHLO outside the submitted work.

Funding Statement

This study was funded by the University of Namur

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Medical Ethical Committee of Saint-Luc Bouge (Bouge, Belgium, approval number B0392020000005)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the corresponding author

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted November 21, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity
Julien Favresse, Jean-Louis Bayart, Clara David, Constant Gillot, Grégoire Wieërs, Gatien Roussel, Guillaume Sondag, Marc Elsen, Christine Eucher, Jean-Michel Dogné, Jonathan Douxfils
medRxiv 2021.11.18.21266478; doi: https://doi.org/10.1101/2021.11.18.21266478
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity
Julien Favresse, Jean-Louis Bayart, Clara David, Constant Gillot, Grégoire Wieërs, Gatien Roussel, Guillaume Sondag, Marc Elsen, Christine Eucher, Jean-Michel Dogné, Jonathan Douxfils
medRxiv 2021.11.18.21266478; doi: https://doi.org/10.1101/2021.11.18.21266478

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (413)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (248)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (393)
  • Epidemiology (8550)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1744)
  • Geriatric Medicine (167)
  • Health Economics (371)
  • Health Informatics (1237)
  • Health Policy (619)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10281)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1670)
  • Nursing (97)
  • Nutrition (248)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (926)
  • Ophthalmology (263)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (112)
  • Palliative Medicine (40)
  • Pathology (252)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (247)
  • Primary Care Research (207)
  • Psychiatry and Clinical Psychology (1764)
  • Public and Global Health (3832)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (319)
  • Respiratory Medicine (520)
  • Rheumatology (207)
  • Sexual and Reproductive Health (165)
  • Sports Medicine (157)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (74)